Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill
  
The Section 232 investigation gives generic manufacturers an opportunity to highlight supply chain vulnerabilities. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Generics

More from Biosimilars & Generics